Host: Jennifer Caudle, DO

Guest: Richard Channick, MD

Please see the full Prescribing Information here.

This program is intended for US healthcare professionals only and is not certified for continuing medical education. Sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Pulmonary arterial hypertension (PAH) is a progressive disease that falls under the broader category of pulmonary hypertension.1 Newly diagnosed patients with PAH have a poor prognosis and disease progression is inevitable.2-5 Enormous strides have been made over the past two decades in advancing understanding and treatment of the disease.2

Dr. Richard N. Channick, a Professor of Medicine and Director of the Pulmonary Vascular Disease Program at UCLA Medical Center, joins ReachMD host Dr. Jennifer Caudle to discuss data that explore earlier initiation of treatment for patients with PAH.6,7

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI is contraindicated.

WARNINGS AND PRECAUTIONS
Pulmonary Veno-Occlusive Disease (PVOD)
Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI.

ADVERSE REACTIONS
Adverse reactions more frequent compared to placebo (≥3%) are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs ...